Cargando…
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, yet no effective therapeutics exist. This review provides an overview of the recent development of recombinant immunotoxins for the treatment of glypican-3 (GPC3) expressing HCC. GPC3 is a cell surface heparan sulfate pr...
Autores principales: | Fleming, Bryan D., Ho, Mitchell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086635/ https://www.ncbi.nlm.nih.gov/pubmed/27669301 http://dx.doi.org/10.3390/toxins8100274 |
Ejemplares similares
-
Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update
por: Fleming, Bryan D., et al.
Publicado: (2020) -
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016) -
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis
por: Gao, Wei, et al.
Publicado: (2015) -
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma
por: Liu, Xiaoyu, et al.
Publicado: (2020) -
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer
por: Kolluri, Aarti, et al.
Publicado: (2019)